History A 35 year journey with a relentless focus on science
Our commitment to patients extends well beyond our labs. We are proud to support the communities we serve, to embrace a culture and business model of patients over profits and to hold the highest ethical standards when it comes to patient well-being.
Regeneron is founded by Leonard S. Schleifer, MD, PhD, a young neurologist and assistant professor at Cornell University Medical College
George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Regeneron
Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year
We announce a collaboration to develop neurotrophic factors
REGN stock begins trading publicly on the NASDAQ; the initial public offering (IPO) raises $91.6 million
Clinical development of our first investigational drug, a neurotrophic factor, begins
We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved medicine
Industry legend P. Roy Vagelos, MD becomes chairman of the board
Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly
The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions
George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world
Our investigational medicine rilonacept begins clinical exploration
Our first paper on VelociGene® is published, introducing the world to our proprietary Veloci technologies
We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students
Our investigational medicine aflibercept begins clinical development
Sarilumab, our first fully human antibody, enters clinical development
A collaboration with Bayer HealthCare focuses on developing aflibercept outside the U.S.
A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune® technology platform
The FDA approves our first medicine, ARCALYST® (rilonacept) Injection
*In 2021, Kiniksa assumed U.S. commercial rights to ARCALYST for all approved indications
We expand and extend our antibody collaboration with Sanofi
Our investigational medicine alirocumab begins clinical development
We hire our 1,000th employee and move into new buildings on our Tarrytown campus
We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts
-Injection.png "EYLEA® (aflibercept) Injection")
The FDA approves EYLEA® (aflibercept) Injection for its first indication
Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year®
The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry
Scrip Intelligence names us Biotech Company of the Year
We announce the first recipients of our annual Regeneron Prize for Creative Innovation
Our European business office opens in Dublin, Ireland
Scrip Intelligence names Len and George as the "Management Team of the Year"
The Regeneron Genetics Center®, a new human genetics initiative, officially launches
We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields. Learn more about our initiatives
We begin building our first ex-U.S. IOPS site in Limerick, Ireland
The FDA approves PRALUENT® (alirocumab) Injection our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody
We launch a major new immuno-oncology collaboration with Sanofi
We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)
The FDA approves DUPIXENT® (dupilumab) Injection, our fifth FDA-approved medicine
The FDA approves KEVZARA® (sarilumab) Injection, our sixth FDA-approved medicine and second fully human monoclonal antibody
Recognized on the Civic 50 list of most community-minded companies in the United States
The FDA approves a new indication for DUPIXENT® (dupilumab) Injection
The FDA approves Libtayo® (cemiplimab-rwlc) Injection, our seventh FDA-approved medicine
Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education. Society for Science announces Regeneron as new sponsor of the International Science and Engineering Fair
The FDA and European Commission approves new indications for EYLEA® (aflibercept) injection, DUPIXENT® (dupilumab) injection, Libtayo® (cemiplimab) injection and PRALUENT® (alirocumab) injection
Regeneron debuts on the prestigious Dow Jones Sustainability World Index of Most Sustainable Companies
The FDA approves an expanded indication for DUPIXENT® (dupilumab) injection
The FDA approves Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn)
Regeneron discovers and develops novel COVID-19 antibody cocktail in record time; FDA authorizes for emergency use
Regeneron named Science magazine’s #1 biopharma company for the seventh time
The FDA approves new indications for Libtayo® (cemiplimab-rwlc) injection and DUPIXENT® (dupilumab) injection; European Commission approves a new indication for Libtayo® (cemiplimab) injection
The European Commission authorizes Regeneron’s COVID-19 antibody cocktail
Regeneron and Intellia announce first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing
Regeneron Genetics Center discovers GPR75 gene mutations that protect against obesity
The FDA and European Commission approve new indications for DUPIXENT® (dupilumab) injection
Regeneron takes full ownership of Libtayo® (cemiplimab) injection, with exclusive worldwide development, commercialization and manufacturing rights
The FDA approved Libtayo in first-line NSCLC in combination with chemotherapy in the fourth quarter of 2022
Regeneron acquires Checkmate Pharmaceuticals, deepening its immuno-oncology portfolio
Regeneron awarded the 2022 Prix Galien USA Best Biotechnology Product for Inmazeb®
Industry luminary P. Roy Vagelos, M.D. retires as board chair
Drs. Leonard S. Schleifer and George D. Yancopoulos become co-Chairs of the board
The FDA approves Veopoz™ (pozelimab-bbfg), our tenth FDA-approved medicine
The FDA approves EYLEA® HD (aflibercept) Injection 8 mg, our eleventh FDA-approved medicine
There may be no other thing you can do that is more rewarding than to really move the human condition forward
George D. Yancopoulos, MD, PhD
Board co-Chair, President and Chief Scientific Officer